MAPT and Alzheimer disease: In addition, in patients with low/medium tau, 47% showed no disease progression for at least one year compared to 29% on placebo. The study showed that for patients with mild dementia from AD, donanemab slowed disease progression by 32% over 18 months, and the difference was significant [126].